Tyvaso 0.6 MG refill kit
Ended Awarded Last action
- Contract number
- 36C24526N0494
- Awardee
-
United Therapeutics Corp UEI KK5FBFA43JS7
- Awarding agency
-
Veterans Integrated Service Network 5
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $0
Award facts
- Contract value
- $0.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Lake Mary, FL 32746, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$15,746 | |
| Original award | $15,746 |
About this award
The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 5 (VISN 5), awarded a delivery order to United Therapeutics Corp for Tyvaso 0.6 mg refill kits with a ceiling value of $15,746.12. This firm fixed-price delivery order, executed on April 8, 2026, with an ultimate completion date of April 10, 2026, operates under the company's single-award Blanket Purchase Agreement with the VA National Acquisition Center valued at $207.1 million. The agreement, established under the General Services Administration's Federal Supply Schedule for Pharmaceuticals and Drugs (FSS-61-IB), enables the VA to procure specialized medications at pre-negotiated prices without additional competition. Performance will be conducted in Lake Mary, Florida, and no set-aside designation was applied to this contract.
United Therapeutics Corp, a biotechnology manufacturer headquartered in Silver Spring, Maryland, specializes in developing treatments for rare and life-threatening conditions including pulmonary arterial hypertension. Tyvaso (treprostinil) inhalation solution is a critical pharmaceutical product supplied through the BPA alongside three other key medications: Unituxin, Remodulin, and Orenitram. This delivery order represents one of numerous individualized purchase orders issued across multiple Veterans Integrated Service Networks nationwide, supporting the VA's mission to ensure reliable access to these specialized medications for veterans requiring treatment for pulmonary arterial hypertension and select oncology conditions.
Quick answers
Who was awarded contract 36C24526N0494?
36C24526N0494 was awarded to United Therapeutics Corp by Veterans Integrated Service Network 5 (Veterans Health Administration) on April 8, 2026.
How much is contract 36C24526N0494 worth?
The government has obligated $0 on 36C24526N0494.
Is contract 36C24526N0494 an order under another contract?
Yes. 36C24526N0494 is a delivery order under 36F79720D0104, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C24526N0494 competed?
The extent of competition for 36C24526N0494 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award